Table 1.
Clinicopathological characteristics of the tumours included in the study, considered together and by cell lineage
| All tumours n = 54 | Gonadotroph n = 26 | Pit1 lineage n = 20 | Corticotroph n = 8 | |
|---|---|---|---|---|
| Age at surgery (years) | 56 (27–87) | 63 (37–87) | 49 (27–77) | 52 (33–66) |
| Gender | ||||
| Female | 32 (59%) | 12 (46%) | 14 (70%) | 6 (75%) |
| Male | 22 (41%) | 14 (54%) | 6 (30%) | 2 (25%) |
| Sample localization | ||||
| Tumour tissue | 54 (100%) | 26 (100%) | 20 (100%) | 8 (100%) |
| Adjacent anterior pituitary | 9 (17%) | 2 (8%) | 5 (25%) | 2 (25%) |
| Maximal diameter (mm)* | 24 (5–60) | 30 (20–55) | 21 (7–60) | 15 (5–32) |
| n = 45 | n = 22 | n = 16 | n = 7 | |
| Invasion | ||||
| Yes | 28 (52%) | 15 (58%) | 9 (45%) | 4 (50%) |
| No | 18 (33%) | 7 (27%) | 9 (45%) | 2 (25%) |
| NA | 8 (15%) | 4 (15%) | 2 (10%) | 2 (25%) |
| Proliferation | ||||
| No | 46 (85%) | 23 (88%) | 16 (80%) | 7 (88%) |
| Yes | 8 (15%) | 3 (12%) | 4 (20%) | 1 (12%) |
| Ki67 index | ||||
| < 3% | 43 (80%) | 22 (85%) | 16 (80%) | 5 (62%) |
| ≥ 3% | 11 (20%) | 4 (15%) | 4 (20%) | 3 (38%) |
| Mitosis | ||||
| ≤ 2/10 HPFs | 47 (87%) | 22 (85%) | 18 (90%) | 7 (88%) |
| > 2/10 HPFs | 7 (13%) | 4 (15%) | 2 (10%) | 1 (12%) |
| p53 | ||||
| Negative | 43 (80%) | 24 (92%) | 12 (60%) | 7 (88%) |
| Positive | 11 (20%) | 2 (8%) | 8 (40%) | 1 (12%) |
| Grade | ||||
| 1a | 17 (31%) | 6 (23%) | 9 (45%) | 2 (25%) |
| 1b | 1 (2%) | 1 (4%) | 0 (0%) | 0 (0%) |
| 2a | 23 (43%) | 13 (50%) | 6 (30%) | 4 (50%) |
| 2b | 5 (9%) | 2 (8%) | 3 (15%) | 0 (0%) |
| NA | 8 (15%) | 4 (15%) | 2 (10%) | 2 (25%) |
| Functioning status | ||||
| Functioning | 24 (44%) | 0 (0%) | 20 (100%) | 4 (50%) |
| Non-functioning | 30 (56%) | 26 (100%) | 0 (0%) | 4 (50%) |
*The only characteristic for which n is different than the one noted on the first row
The age at surgery and the maximal diameter are expressed as mean with range
Invasion = cavernous and/or sphenoid sinus invasion detected on magnetic resonance imaging and/or during surgery
Proliferation = two of three criteria of proliferation present, namely Ki67 index ≥ 3%, mitoses n > 2/10 high power fields (HPFs) (400 × magnification), and positive p53 (> 10 strongly positive nuclei/10 HPFs)
number (n), not available (NA)